Imatinib is a type II (binds to the inactive state kinase) adenosine triphosphate competitive inhibitor of Abl (and Bcr-Abl), KIT and platelet-derived growth factor receptor (PDGFR) kinases, one of the first cancer-targeted therapies [24]. This evidence concerns the gene ABL1 and cancer.